Ianalumab

伊利尤单抗

Report date: 2026/05/06 20:02:28

Base Information

Drug NameIanalumab
Drug Alias NameNVP-VAY736VAY-736NOV-5
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionB-cell activating factor receptor inhibitorsAdvanced glycosylation end product modulatorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsB-cell activating factor receptorAdvanced glycosylation end product
Therapy Area/IndicationsEvans syndromeCytopeniaPemphigus +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[49] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesMorphosys AgNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Schweiz AgNovartis Pharma AgNovartis Pharma Stein Ag +[5] 
Inactive CompaniesN/A
Active IndicationsEvans syndromeCytopeniaScleroderma, Diffuse +[14] 
Inactive IndicationsPemphigusMultiple SclerosisIdiopathic Pulmonary Fibrosis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A